Thursday, 15 October 2015

Valeant Pharmaceuticals Under Federal Investigation For Drug Pricing Practices

In other news, Bloomberg examines an effort by top cancer hospitals to provide patients with information about the cost of the drugs used in their treatments. Meanwhile, The Wall Street Journal takes a look at Theranos, and The Washington Post reports that a watchdog group has thrown up a red flag regarding the Food and Drug Administration's review of a blood-thinning drug.

No comments:

Post a Comment